An Affinity Threshold for Maximum Efficacy in Anti-PD-1 Cancer Immunotherapy
Monoclonal antibodies (mAbs) targeted to the programmed cell death protein 1 (PD-1) remain the most prevalent cancer immunotherapy both as a monotherapy and in combination with additional therapies. Despite the extensive success of anti-PD-1 mAbs in the clinic, the experimental relationship between...
| Auteur principal: | |
|---|---|
| Autres auteurs: | |
| Format: | Thèse |
| Publié: |
Massachusetts Institute of Technology
2022
|
| Accès en ligne: | https://hdl.handle.net/1721.1/144968 https://orcid.org/ 0000-0002-2246-6333 |